SOSV

InnSight Technology is a biotechnology company focused on advancing the diagnostics and evaluation of eye diseases. The company specializes in developing innovative ophthalmic devices, including a novel, hand-held biosensor designed for the detection of anterior ophthalmic injuries. Additionally, InnSight Technology works on the development of nanotechnology-based medical devices aimed at addressing various clinical needs in ophthalmology. By providing these advanced tools, the company enables clinicians to enhance ocular care and improve patient outcomes in eye health.

Sharper Sense develops wearable neurotechnology to enhance vision, hearing, and touch. The company focuses on a neuromodulation patch that delivers non-invasive electrical stimulation to improve sensory acuity and perception, with potential applications for processing disorders and sensory loss, and to boost performance, enabling clearer, more accurate perceptions for improved task precision and safety.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Ostoform is a Dublin, Ireland-based medical device company focused on ostomy skin health. It develops patented devices designed to manage skin complications for ostomy patients, including OSTOFORM, a mouldable seal that wraps around the stoma, and FLOWASSIST, which directs stoma output away from the skin. The technology is designed to prevent skin contact with corrosive output, reduce leakage, and improve skin health. The business originated as a spin-out from the University of Limerick and was established in 2016, leveraging patented technology to scale its solutions globally.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

Serene Sleep is a medical technology company that focuses on improving sleep quality by addressing snoring and sleep apnea. It develops and offers a non-invasive, targeted treatment procedure using palatal implants, designed to reduce disruptive snoring and enhance overall sleep for both the individual and their partner.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Founded in 2021, Samphire Neuroscience specializes in developing neurotechnological solutions for women's health. Its flagship product is a non-invasive headband device that uses electrical neuromodulation to alleviate symptoms such as pain, fatigue, and mood changes associated with menstrual cycles.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Medical Devices, Kidney Disease, Wearables, Medtech, Hardtech

Founded in 2014, Machine Medicine Technologies develops an AI-powered platform for objective measurement of movement disorders like Parkinson's disease. Using computer vision and pose estimation techniques, it tracks patient movements to provide secure, accessible, and affordable metrics for researchers and healthcare providers.

VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. Its lead product, a first-in-class non-invasive eyedrop, aims to replace invasive injections for conditions like age-related macular degeneration and diabetic macular edema.

Exosomm is an innovative foodtech start-up focused on developing nutritional solutions derived from natural milk exosomes. The company was founded based on research from Hadassah Medical Center, led by Prof. Reif's team. Exosomm's flagship product is a specialized food formula designed for patients suffering from inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. This product utilizes a patented active anti-inflammatory ingredient sourced from milk exosomes, which are isolated using a natural and environmentally friendly process. By targeting health and immunity, Exosomm aims to provide effective solutions for individuals with specific dietary needs.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

DisperseBio is a Biotechnology Research firm developing a mechanism to counter microbial contamination on natural surfaces like human body.

Metabolic Psychiatry Labs is a mental healthcare company that provides remote treatment solutions for mental illnesses. Their platform integrates metabolic and mental health research, data tracking, metabolic interventions, and personalized medical care, enabling patients to receive effective treatments from home. The company offers assessments, lab tests, and wellness solutions based on metabolic therapy.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Minutia is a biotechnology company focused on developing innovative stem cell-derived transplants aimed at treating Type 1 Diabetes. The company specializes in creating insulin-producing cell transplants that incorporate proprietary nanosensors, allowing for real-time monitoring of transplant status. These immune-evasive cells are designed for subcutaneous implantation, addressing common challenges associated with transplant procedures. By advancing this technology, Minutia seeks to transform the clinical landscape for diabetes management and cell replacement therapies, ultimately working towards a functional cure for this condition.

Calyx develops advanced sensor platforms that monitor various parameters in poultry farming with exceptional specificity and sensitivity. The company combines AI computer vision technology, bio-engineered sensors, and data science to address complex challenges in the poultry industry.

Bloomlife is a pioneering company in maternal health, leveraging connected devices and cloud-based data analytics to enhance access to care for expectant mothers. Its innovative solution enables obstetricians to more efficiently screen and manage pregnancy complications, empowering women and reducing geographical barriers.

Tinkeso Therapeutics is a biotechnology company specializing in the development of innovative, off-the-shelf cell therapies for treating cancer and autoimmune diseases. The company focuses on creating allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies, which use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions. This approach aims to increase treatment accessibility and scalability by utilizing non-patient-specific cells.

heXem bio specializes in recording solutions for the early development of humans for longevity.

Zhenshi Medical is a medical device company that specializes in lung puncture medical robots for diagnosing and treating lung cancer.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

DeepSpin GmbH, founded in 2019 and based in Berlin, Germany, specializes in the development of an innovative artificial intelligence-powered magnetic resonance imaging (MRI) system. The company's technology aims to significantly reduce the cost, size, and weight of traditional MRI machines, thereby enhancing accessibility to medical imaging for patients worldwide. By utilizing generative topological design for its hardware and deep learning techniques for image processing, DeepSpin's MRI system seeks to make advanced medical imaging available in a variety of previously underserved healthcare settings. This approach not only aims to improve patient care but also to democratize access to essential medical diagnostics globally.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

kegg is a fertility health tracking device from a San Francisco based company founded in 2017 that combines fertility tracking with pelvic floor exercises. The device analyzes changes in cervical fluids to detect the fertile window and ovulation up to seven days in advance, providing users with information to guide conception decisions. By collecting data from cervical fluids, it aims to support women’s health through improved diagnosis, monitoring, and planning related to fertility.

VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. Its lead product, a first-in-class non-invasive eyedrop, aims to replace invasive injections for conditions like age-related macular degeneration and diabetic macular edema.

OncoPrecision develops a patient micro avatar platform that uses single-cell high-throughput biology and machine learning to provide comprehensive patient-derived phenotypic biomarkers. This enables oncologists to tailor cancer therapy across modalities, improving patient success through data-driven decisions based on patient-derived samples.

Founded in 2015, GlowDx specializes in developing point-of-care diagnostic platforms. Utilizing novel molecular technology and machine learning, the company aims to democratize access to diagnostics globally, enabling timely detection of infectious diseases and reducing disease burden.

FeetMe is a digital health company that develops a platform and connected footwear insoles for gait and movement analysis in-clinic and real-world settings. The technology combines pressure sensors, motion data, and learning algorithms to provide real-time gait and posture insights and digital biomarkers to support clinical research and improve care for patients with movement disorders and mobility constraints. These insights enable clinicians to monitor disease progression, tailor treatments, and optimize medication use by assessing mobility capacity and tracking changes over time.

VisusNano Ltd. is a London-based company founded in 2016 that specializes in the development of a drug-eluting intraocular lens implant designed for use in cataract surgery. This innovative technology aims to enhance patient outcomes by reducing the risks associated with the procedure, such as intraocular inflammation, infection, and opacification. By eliminating the need for postoperative eye drops and minimizing the necessity for laser treatments, VisusNano's product has the potential to transform cataract surgery for both human and veterinary patients. The company is currently in the pre-clinical stage of its development.

Lief Therapeutics is a medical device company based in San Francisco, California, focused on enhancing at-home care for individuals dealing with post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet bio-sensing patch that accurately measures heart rate and breath, allowing users to manage their natural stress response through vibratory biofeedback exercises. This wearable device helps users monitor their behaviors, emotions, and thoughts in real-time, fostering mindfulness and control throughout the day. Additionally, it supports clinicians by tracking patient progress, facilitating in-session training, and scheduling psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, enabling users to track daily progress and engage in tailored exercises. Founded in 2014, the company sells its products online, aiming to empower individuals in their mental health journeys.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Level Zero Health is a technology company specializing in advanced biosensor solutions. It develops wearable devices equipped with DNA-based sensors, designed to precisely monitor key endocrine biomarkers in real-time. By combining biochemistry and nanotechnology, the company collects novel data, empowering users to gain insights into their hormonal health.

Strados Labs, LLC is a medical technology company based in Philadelphia, Pennsylvania, specializing in respiratory health management through innovative sensor-based solutions. Founded in 2016, the company has developed a wearable device that provides real-time insights into breathing patterns, sounds, and speed. This device is equipped with clinical-grade biosensors and smart software, allowing for continuous monitoring of respiratory conditions such as asthma and chronic obstructive pulmonary disease. By connecting to a mobile application, Strados enables users and healthcare providers to access and analyze respiratory data, facilitating informed health decisions and remote patient monitoring.

Founded in 2021, Samphire Neuroscience specializes in developing neurotechnological solutions for women's health. Its flagship product is a non-invasive headband device that uses electrical neuromodulation to alleviate symptoms such as pain, fatigue, and mood changes associated with menstrual cycles.

XN Health is a medical device company founded in 2021 and based in Texas, USA. The company focuses on developing innovative healthcare solutions to assist mechanically ventilated patients in weaning off ventilators more efficiently. Its primary product utilizes phrenic nerve stimulation to induce diaphragm contractions, thereby mitigating the risks of diaphragm dysfunction associated with prolonged mechanical ventilation. By enhancing the weaning process, XN Health aims to improve patient outcomes and facilitate recovery in critical care settings.

Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the development of treatments for complex diseases such as cancer and age-related disorders.

Feel Therapeutics is a digital health company specializing in precision medicine for mental health. It develops physiological and digital biomarkers using advanced computer science methods, leveraging wearable devices to collect and analyze biometric data.

Chronus Health develops a portable diagnostic device for delivering point-of-care lab results in minutes. Its device enables real-time diagnosis at the point-of-care, improving time to care and patient outcomes.

Founded in 2011, Verdex Technologies specializes in the mass production of non-toxic nanofibers using proprietary green technology. The company designs, patents, and licenses equipment for filtration and biomedical purposes, creating advanced performance nanofiber materials for various applications such as engine filters, liquid filters, industrial air filters, waterproof textiles, medical packaging, and face masks.

Lura Health develops a non-invasive continuous health monitoring platform that uses saliva as a diagnostic fluid. The company integrates micro-sensors into orthodontic devices such as retainers, aligners, and brackets to continuously measure saliva analytes and securely transmit data to a smartphone app, enabling users to monitor oral health metrics and potentially support broader chronic disease management. Target markets include heart disease, chronic kidney disease, diabetes, and tooth decay. Founded in 2017, the company is based in Cambridge, Massachusetts.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.

Hypercell Technologies develops tools to control infectious diseases in animals, including diagnostics and monoclonal antibodies designed to curb viruses in production animal reservoirs. The company employs molecular biology to create rapid, on-farm diagnostics that enable veterinarians to detect infections quickly and implement preventive measures. By focusing on proactive control of viruses in animal populations, Hypercell aims to reduce the emergence of diseases that could threaten human health and improve animal health management across production settings.

FluidAI is a medical technology company focused on post-operative care, combining artificial intelligence with in-body data to improve patient monitoring. The company develops a smart catheter system that enables proactive post-operative care by detecting complications at onset and delivering critical health data to healthcare providers ahead of time.

Vivo Care develops a remote care software platform that supports remote patient monitoring and chronic disease management. The platform integrates patient-centered monitoring technology, connected devices, and clinical support to help healthcare providers deliver equitable care across diverse patient populations, improve patient outcomes, and modernize the patient experience. It enables scalable deployment of RPM and chronic care management programs, enhances patient engagement, and aims to deliver compliant and reliable reimbursement revenue for providers, supporting both clinical and financial results.

Founded in 2018, Rizlab Health specializes in developing compact blood diagnostic devices. Their flagship product is CytoTracker, a pocket-sized, wireless analyzer powered by artificial intelligence, designed to deliver rapid and affordable white blood cell count analysis.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

Medical Devices, Kidney Disease, Wearables, Medtech, Hardtech

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

LightHearted AI is a company that specializes in developing an AI-driven remote cardiovascular diagnostics tool aimed at improving the detection of heart conditions. This medical device is designed to deliver rapid, precise, and cost-effective assessments, addressing the critical need to prevent heart-related deaths. By leveraging advanced technology, LightHearted AI enhances the capabilities of healthcare professionals, allowing for faster and more accurate diagnostic procedures compared to traditional methods. The company's innovation seeks to transform cardiac care, ultimately contributing to better treatment outcomes for patients.

Xias Bio is a biotechnology company focused on producing recombinant proteins. It specializes in creating advanced soluble ingredients with improved attributes such as enhanced gel and film formation, and antioxidant properties. The company's core expertise lies in developing non-immunogenic natural motifs to deliver functionalities for research, beauty, and healthcare applications.

MedIQ is an integrated virtual care platform providing on-demand healthcare at the point of need. MedIQ redefines healthcare through a digitally enabled, cashless, hybrid healthcare ecosystem. MedIQ makes high-quality, modernized healthcare and wellness available to everyone.

Founded in 2014, QuantumCyte develops an automated tissue dissection system that uses digital maps to isolate regions of interest containing informative biomarkers. This platform aims to improve cancer outcomes by enabling precise cellular data analysis for predicting drug efficacy.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

Founded in 2009 by Rhona Togher and Eimear O’Carroll, Lios is dedicated to combating noise pollution through innovative acoustic materials and technologies. The company's flagship product, SoundBounce, is a revolutionary acoustic material used in industries such as automotive, aerospace, construction, and power generation, offering significant improvements in noise reduction compared to traditional solutions.

Feel Therapeutics is a digital health company specializing in precision medicine for mental health. It develops physiological and digital biomarkers using advanced computer science methods, leveraging wearable devices to collect and analyze biometric data.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Founded in 2011, Verdex Technologies specializes in the mass production of non-toxic nanofibers using proprietary green technology. The company designs, patents, and licenses equipment for filtration and biomedical purposes, creating advanced performance nanofiber materials for various applications such as engine filters, liquid filters, industrial air filters, waterproof textiles, medical packaging, and face masks.

TippingPoint Biosciences is developing therapeutics that target abnormal DNA packaging states in diseases such as cancer.

VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. Its lead product, a first-in-class non-invasive eyedrop, aims to replace invasive injections for conditions like age-related macular degeneration and diabetic macular edema.

Founded in 2021, Samphire Neuroscience specializes in developing neurotechnological solutions for women's health. Its flagship product is a non-invasive headband device that uses electrical neuromodulation to alleviate symptoms such as pain, fatigue, and mood changes associated with menstrual cycles.

Vivo Care develops a remote care software platform that supports remote patient monitoring and chronic disease management. The platform integrates patient-centered monitoring technology, connected devices, and clinical support to help healthcare providers deliver equitable care across diverse patient populations, improve patient outcomes, and modernize the patient experience. It enables scalable deployment of RPM and chronic care management programs, enhances patient engagement, and aims to deliver compliant and reliable reimbursement revenue for providers, supporting both clinical and financial results.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Leadoptik specializes in developing miniature imaging platforms that enhance minimally invasive interventions. Its technology offers high-resolution imaging and real-time 3D navigation capabilities, aiding surgeons in detecting early-stage cancers.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

AvantGuard creats innovative solutions that manage surfaces and provide long-term protection against viruses, bacteria, and fungi/mold, in a variety of applications.

Kresko RNAtech is a biotechnology company specializing in the development and production of nutraceuticals. It employs advanced techniques such as machine learning and bioinformatics to identify beneficial ribonucleic acids (RNAs) from natural sources, aiming to enhance human health and well-being.

Geltor designs and produces animal-free collagen and other bioactive proteins for beauty, wellness, and nutrition applications. Founded in 2015, the company uses proprietary AI to create customized proteins tailored to specific industry needs.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

AuraSense employs AI and automation to convert subjective neurological examinations into objective, quantifiable data. This enables neurologists to accurately assess their patients' cognitive and physical health.

Beeflow is a biotechnology-driven company that applies science and technology to bee pollination. The company provides professional pollination services to farmers, leveraging proprietary pollination technologies, data-driven hive management, and expertise in bee biology and crop science to optimize pollination and improve crop quality for crops such as blueberries, almonds, raspberries, and kiwifruit. Operating in the United States, Peru, and Mexico, Beeflow began in Argentina and has expanded to international markets, aiming to increase crop yields while supporting bee health and sustainability.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Kolibri specializes in developing innovative bioreactors that significantly enhance cell culture yields while reducing production costs. Their proprietary platform, combining cutting-edge acoustics and biology techniques, aims to make cell and gene therapies more accessible and affordable.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

Mimio Health is a nutraceutical company specializing in the research and production of mimetic supplements. Its patent-pending fasting mimetic formulation replicates the body's natural response to fasting by using a rigorously selected combination of bioactive human metabolites, inducing regenerative effects without requiring actual fasting.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

R-Zero specializes in smart building technology, providing real-time insights to optimize indoor spaces. Their solutions include Indoor Air Quality (IAQ) monitoring, energy-efficient HVAC systems, space utilization sensors, and occupancy-based controls. The platform is user-friendly, secure, scalable, and helps prepare buildings for future challenges.

Japet Medical is a French biomedical company specializing in the development of robotic medical devices. Their focus lies in creating efficient and user-friendly solutions designed to enhance treatment quality and improve patients' lives.